Literature DB >> 26587327

Retargeted oncolytic viruses provoke tumor-directed T-cell responses.

Arnold Kloos1, Norman Woller2, Rita Gerardy-Schahn3, Florian Kühnel2.   

Abstract

Intratumoral application of oncolytic viruses effectively induce tumor-directed immune responses. However, their systemic application is typically insufficient to stimulate the required extent of tumor tissue inflammation to elicit antitumor immunity. We recently discovered evidence that this barrier can be overcome by effective molecular retargeting of viral infection.

Entities:  

Keywords:  oncolytic virus, molecular retargeting, neoepitope-specific T cell responses

Year:  2015        PMID： 26587327      PMCID： PMC4635698          DOI： 10.1080/2162402X.2015.1052933

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

2.  Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice.

Authors:  Norman Woller; Sarah Knocke; Bettina Mundt; Engin Gürlevik; Nina Strüver; Arnold Kloos; Bita Boozari; Peter Schache; Michael P Manns; Nisar P Malek; Tim Sparwasser; Lars Zender; Thomas C Wirth; Stefan Kubicka; Florian Kühnel
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

3.  The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.

Authors:  Volker Lennerz; Martina Fatho; Chiara Gentilini; Roy A Frye; Alexander Lifke; Dorothea Ferel; Catherine Wölfel; Christoph Huber; Thomas Wölfel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-24       Impact factor: 11.205

4.  PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.

Authors:  Arnold Kloos; Norman Woller; Engin Gürlevik; Cristina-Ileana Ureche; Julia Niemann; Nina Armbrecht; Nikolas T Martin; Robert Geffers; Michael P Manns; Rita Gerardy-Schahn; Florian Kühnel
Journal:  Cancer Immunol Res       Date:  2015-02-19       Impact factor: 11.151

5.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors:  Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

6.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 7.  The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Authors:  Robin J Prestwich; Fiona Errington; Rosa M Diaz; Hardev S Pandha; Kevin J Harrington; Alan A Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2009-10       Impact factor: 5.695

8.  Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

Authors:  Caroline J Breitbach; Rozanne Arulanandam; Naomi De Silva; Steve H Thorne; Richard Patt; Manijeh Daneshmand; Anne Moon; Carolina Ilkow; James Burke; Tae-Ho Hwang; Jeong Heo; Mong Cho; Hannah Chen; Fernando A Angarita; Christina Addison; J Andrea McCart; John C Bell; David H Kirn
Journal:  Cancer Res       Date:  2013-02-07       Impact factor: 12.701

9.  Polysialylated neuropilin-2 is expressed on the surface of human dendritic cells and modulates dendritic cell-T lymphocyte interactions.

Authors:  Sabrina Curreli; Zita Arany; Rita Gerardy-Schahn; Dean Mann; Nicholas M Stamatos
Journal:  J Biol Chem       Date:  2007-08-15       Impact factor: 5.157

10.  Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter.

Authors:  Hua-Jung Li; Maaike Everts; Larisa Pereboeva; Svetlana Komarova; Anat Idan; David T Curiel; Harvey R Herschman
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701
  10 in total
  3 in total

Review 1.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

Review 2.  Oncolytic Virotherapy in Peritoneal Metastasis Gastric Cancer: The Challenges and Achievements.

Authors:  Su Shao; Xue Yang; You-Ni Zhang; Xue-Jun Wang; Ke Li; Ya-Long Zhao; Xiao-Zhou Mou; Pei-Yang Hu
Journal:  Front Mol Biosci       Date:  2022-02-28

3.  Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma.

Authors:  Irene Appolloni; Francesco Alessandrini; Laura Menotti; Elisa Avitabile; Daniela Marubbi; Noemi Piga; Davide Ceresa; Francesca Piaggio; Gabriella Campadelli-Fiume; Paolo Malatesta
Journal:  Viruses       Date:  2021-08-24       Impact factor: 5.048
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.